Neuroinflammatory signaling
PEA and selected fatty acids have been studied for their roles in pathways involved in inflammatory balance.
The science behind OnLife®
A Targeted, Multi-Pathway Approach to Nerve Health
Novilora™ is the U.S. product name for OnLife®, a formulation that combines palmitoylethanolamide (PEA) with a defined profile of specific fatty acids selected for their roles in nerve structure, signaling and cellular function.
Biological rationale
Five pathways involved in nerve health
These pathways explain the scientific rationale for the formulation. They do not, by themselves, establish clinical efficacy.
Cell-membrane biology
Fatty acids are structural components of neuronal cell membranes.
Targeted formula
Fatty acids
+ PEA
Cellular energy
Healthy nerve function depends on mitochondrial and cellular energy processes.
Myelin + Schwann cells
Lipids are important structural components of myelin and peripheral nerve biology.
Nerve signaling
Healthy neuronal membranes and ion-channel activity contribute to normal nerve communication.
Built around lipid biology
PEA + a defined fatty-acid profile
EPA + DHA
Alpha-Linolenic Acid
Linoleic Acid
Oleic Acid
Palmitic Acid + Stearic Acid
The formulation story is the combination of specific fatty acids and PEA—not the benefits of one isolated ingredient.
Clinical evidence
Rationale and outcomes are different questions.
The prospective, multicenter, single-arm observational STEFANO study evaluated OnLife® in 146 analyzed patients with established CIPN across 21 oncology centers over three months.
The strongest signal was observed in the paclitaxel-treated breast cancer cohort. Physician-assessed outcomes, patient-reported outcomes, and quality-of-life measures are presented separately in the full study summary.
STEFANO was not randomized or placebo-controlled. It cannot establish how much observed improvement was attributable to OnLife® versus treatment-independent recovery after chemotherapy.
Review the exact resultsPrimary study source
Zaiss M, Uhlig J, Zahn M-O, et al. Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO. Oncology Research and Treatment. 2021. DOI: 10.1159/000519000.